For Immediate Release
Chicago, IL – December 8, 2020 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: NextEra Energy, Inc.
NEE
, Caterpillar Inc.
CAT
, Micron Technology, Inc.
MU
, Dominion Energy, Inc.
D
and Emerson Electric Co.
EMR
.
Here are highlights from Monday’s Analyst Blog:
Top Stock Reports for NextEra, Caterpillar and Micron Technology
The Zacks Research Daily presents the best research output of our analyst team. Today’s Research Daily features new research reports on 16 major stocks, including NextEra Energy, Caterpillar and Micron Technology. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see
all of today’s research reports here >>>
Shares of
NextEra Energy
have gained +23.8% over the past year against the Zacks Utility – Electric Power industry’s decline of -7.1%. The Zacks analyst believes that the company has a well-chalked out capital investment plan to strengthen its infrastructure and add clean assets to the generation portfolio.
NextEra extended long-term growth outlook through 2023 and is on course to achieve the same despite disruptions caused by the pandemic outbreak. It is poised to benefit from $50-$55B investment plan through 2022.
However, its nature of business is subject to complex and comprehensive federal, state, as well as other regulations. If the planned nuclear plant outages last longer or an unplanned outage occurs, the company’s operations and profitability might be hampered.
(You can
read the full research report on NextEra Energy here >>>
)
Caterpillar
shares have outperformed the Zacks Manufacturing – Construction and Mining industry in the year to date period (+23.4% vs. +22.7%), but for the fourth quarter the company anticipates demand to remain weak but at improved levels than the third quarter. A weak backlog, lowering of inventory by dealers and weakness in non-residential construction will impact results in 2020. However, its ongoing cost reduction efforts will sustain margins in this scenario.
Further, a recovering manufacturing sector, resumption of spending at miners, improved North American residential construction and strong construction demand in China hold promise. Further, strong liquidity position, investments in expanded offerings and services and digital initiatives will fuel growth.
(You can
read the full research report on Caterpillar here >>>
)
Micron Technology
shares have gained +36.4% in the year-to-date period against the S&P 500’s rise of +15.1%. The Zacks analyst believes that Micron is witnessing growing demand for memory chips from cloud-computing providers and acceleration in 5G adoptions.
A rising mix of high-value solutions, enhancement in customer engagement and improvement in cost structure are growth drivers as well. Further, 5G (fifth-generation) adoption beyond mobile is likely to spur demand for memory and storage, particularly in IoT (Internet of Things) devices and wireless infrastructure.
Nonetheless, Micron’s near-term performance might be hurt by the bleak memory-chip demand as customers are adjusting inventories in response to the economic recession caused by the coronavirus outbreak. Further, soft server demand from several enterprise OEM (original equipment manufacturer) customers is a concern.
(You can
read the full research report on Micron Technology here >>>
)
Other noteworthy reports we are featuring today include Dominion Energy and Emerson Electric.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released
Century of Biology: 7 Biotech Stocks to Buy Right Now
to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss
.
This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit
https://www.zacks.com/performance
for information about the performance numbers displayed in this press release.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.
Click to get this free report